The Kidney Disease Improving Global Outcomes (KDIGO) guidelines for anemia published in 2012 recommended the administration of ESAs to maintain an Hb level of > 9 g/dL without exceeding 11.5 g/dL [7]. The gene discussed is GSTM1; the disease is anemia.